Alpha-GPC vs Phosphatidylserine
Two cholinergic/phospholipid nootropics with real but dated human trial data — one from dementia trials, the other from a form of the ingredient no longer actually sold.
Alpha-GPC
Choline alfoscerate, choline alphoscerate, L-alpha-glycerylphosphorylcholine
Its strongest human evidence is a randomized dementia trial and an add-on Alzheimer's trial (ASCOMALVA) — not the healthy 'nootropic' population that drives most sales. A 2021 observational analysis also flagged an association with increased 10-year stroke risk that remains unresolved, an open question for anyone with cardiovascular risk factors.
Full Alpha-GPC evidence reviewPhosphatidylserine
PS
The strongest human data comes from older trials using bovine-brain-derived PS, which is no longer sold (BSE concerns); the soy-derived PS on shelves today is chemically different and has a thinner, weaker trial record of its own.
Full Phosphatidylserine evidence reviewSide by side
| Alpha-GPC | Phosphatidylserine | |
|---|---|---|
| Marketed for | Cognitive enhancement / nootropic use, dementia adjunct | Cognitive decline, memory, stress/cortisol |
| Evidence grade | Clinical data | Clinical data |
| Family | mTOR & other | mTOR & other |
| Key human source | De Jesus Moreno Moreno 2003 RCT, Clin Ther | Bovine-PS cognitive decline RCT, Aging Clin Exp Res 1993 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Alpha-GPC's strongest evidence is a randomized Alzheimer's trial and an add-on benefit in treated dementia patients — real, but in a population unlike the healthy users who buy it, plus an unresolved 2021 stroke-risk signal. Phosphatidylserine's strongest data used bovine-brain-derived PS, discontinued after BSE concerns; the soy-derived PS sold today is a chemically different molecule with its own, thinner trial record. Both are cases where the product on the shelf isn't quite the product that was studied.
Alpha-GPC fits if
You want the more actively marketed option, and you don't have elevated cardiovascular risk factors given alpha-GPC's unresolved stroke signal.
Phosphatidylserine fits if
You want to avoid alpha-GPC's stroke-risk question, understanding that today's soy-PS has thinner evidence than the original bovine-PS trials.